Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation
Sponsor: Children's Oncology Group
Listed as NCT00866918, this PHASE3 trial focuses on Childhood Acute Promyelocytic Leukemia With PML-RARA and Myeloid Neoplasm and remains completed. Sponsored by Children's Oncology Group, it has been updated 13 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 8 earlier versions
-
Apr 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Completed → Unknown Status
-
Oct 2019 — Apr 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .